Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

Blood (2019) 134 (Supplement_1): 48.

https://doi.org/10.1182/blood-2019-125967

Published: 2019

Journal Articles

BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Sumithira Vasu, MDMBBS, Nelli Bejanyan, MD, Steven Devine, MD, Elizabeth Krakow, MDMSc, Elizabeth Krakow, MD, Brent Logan, PhD, Leo Luznik, MD, Brittany K Ragon, MD, Emma Barrett, MD, Joe Shan, MPH, BS, Richard E. Champlin, MD

Blood (2019) 134 (Supplement_1): 1955.

https://doi.org/10.1182/blood-2019-128005

Published: 2019

Journal Articles

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

John F. DiPersio, MD PhD, Jonathan Hoggatt, PhD, Steven Devine, MD, Lukasz Biernat, MD, Haley Howell, BS, BA, Veit Schmelmer, PhD, Jason R. Neale, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Kevin A. Goncalves, PhD, Glen D. Raffel, MD PhD, Patrick C. Falahee, PhD, Dwight M. Morrow, PhD, John C. Davis, Jr., MD MPH, MS

Blood (2019) 134 (Supplement_1): 1961.

https://doi.org/10.1182/blood-2019-127523

Published: 2019

Journal Articles

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Blood (2019) 134 (Supplement_1): 4525.

https://doi.org/10.1182/blood-2019-129488

Published: 2019

Journal Articles

BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3- ITD + AML

Mark J. Levis, MD, Mehdi Hamadani, MD, Brent R. Logan, Matt Rosales, David Delgado, Erkut Bahceci, Steven Devine, MD, Mary M. Horowitz, Yi-Bin Chen

Blood (2019) 134 (Supplement_1): 4602.

https://doi.org/10.1182/blood-2019-124322

Published: 2019

Journal Articles

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Andrew Kent, MD PhD, Sumithira Vasu, MDMBBS, Derek Schatz, Natalie Monson, Steven Devine, MD, Clayton Smith, MD, Jonathan A Gutman, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 1311.

https://doi.org/10.1182/blood-2019-127418

Published: 2019

Journal Articles

Impact of I n Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignanciesimpact of I n Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies

Robert J Soiffer, MD, Jennifer LeRademacher, PhD, Vincent T Ho, MD, Fangyu Kan, MD, MS, Andrew Artz, MD, MS, Richard Champlin, Steven Devine, MD, Hillard M. Lazarus, MD, FACP, David I Marks, MB, BS, PHD, David Porter, MD, Edmund K. Waller, MD, PhD, Mary M. Horowitz, MD, MS, Mary Eapen, MBBS

Blood (2010) 116 (21): 2305.

https://doi.org/10.1182/blood.V116.21.2305.2305

Published: 2010

Journal Articles

A Pilot Trial of Two Dose Levels of Rabbit Antithymocyte Globulin, (rATG), Thymoglobulin, as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor Stem Cell Transplant (SCT) with Cyclosporine (CsA) as Graft Versus Host Disease (GvHD) Prophylaxis.

Kenneth B. Miller, MD, Nelson J. Chao, MD, Hans A. Messner, MD,PhD, Steven C. Goldstein, MD, Vijay Reddy, MD,PhD, William Vaughan, MD, Steven Devine, MD, Scott D. Rowley, MD, Ned Waller, MD,PhD, Marcel Devetten, MD, Gary J. Schiller, MD

Blood (2006) 108 (11): 5369.

https://doi.org/10.1182/blood.V108.11.5369.5369

Published: 2006

Journal Articles

Transplantation without Hemolysis in a Kell Antigen Positive Patient Undergoing Peripheral Hematopoietic Stem Cell Transplant from a Donor with Anti-Kell Antibodies.

Regina D. Crawford, MD, David Krugh, William Blum, MD, Steven Devine, MD

Blood (2006) 108 (11): 4137.

https://doi.org/10.1182/blood.V108.11.4137.4137

Published: 2006

Journal Articles

Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy.

David Marin, MD, Michael Mauro, MD, John Goldman, MD, Brian Druker, MD, Steven Devine, MD, Richard E. Clark, MD, Ronald Paquette, MD, Asad Bashey, MD, Martin S. Tallman, MD, April Dovholuk, Axel Hoos, MD, PhD, Pramod Srivastava, PhD

Blood (2005) 106 (11): 1094.

https://doi.org/10.1182/blood.V106.11.1094.1094

Published: 2005

Journal Articles

A Randomized, Double Blind Trial, of Hydroxychloroquine for the Prevention of Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation.

Tom Fong, MD, Kim Trinkaus, PhD, Douglas R. Adkins, MD, Ravi Vij, MD, Steven Devine, MD, Michael Tomasson, MD, Lawrence T. Goodnough, MD, Timothy Graubert, MD, Shalini Shenoy, MD, John F. DiPersio, MD, PhD, Hanna J. Khoury, MD

Blood (2005) 106 (11): 1800.

https://doi.org/10.1182/blood.V106.11.1800.1800

Published: 2005

Journal Articles

AMD3100 + G-CSF Improves Hematopoietic Progenitor Cell (HPC) Collection in Patients with Hodgkin’s Disease (HD).

Amanda Cashen, MD, Steven Devine, MD, Ravi Vij, MD, John DiPersio, MD

Blood (2005) 106 (11): 1979.

https://doi.org/10.1182/blood.V106.11.1979.1979

Published: 2005

NARROW

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3- ITD + AML

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

A Pilot Trial of Two Dose Levels of Rabbit Antithymocyte Globulin, (rATG), Thymoglobulin, as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor Stem Cell Transplant (SCT) with Cyclosporine (CsA) as Graft Versus Host Disease (GvHD) Prophylaxis.

Transplantation without Hemolysis in a Kell Antigen Positive Patient Undergoing Peripheral Hematopoietic Stem Cell Transplant from a Donor with Anti-Kell Antibodies.

Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy.

A Randomized, Double Blind Trial, of Hydroxychloroquine for the Prevention of Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation.

AMD3100 + G-CSF Improves Hematopoietic Progenitor Cell (HPC) Collection in Patients with Hodgkin’s Disease (HD).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only